Shulin He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shulin He has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Conghuang Li
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
2 shared publications - Honggang Zheng
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China
2 shared publications - Baojin Hua
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China
1 shared publication - Baojin Hua
Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication - Bo Yao
School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China
1 shared publication Guanghui Zhang
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Bidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Open AccessBidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- Open Access
- 23 November 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 366
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model
Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has been widely applied to treat lung cancer patients in China. Regulation of the metastatic microenvironment is an important therapeutic approach for prevention and treatment of tumor recurrence and metastasis. The advantage of Traditional Chinese Medicine management of lung cancer lies in the prevention of recurrence and metastasis. Our previous study has demonstrated that FLP ointment could regulate lung inflammatory microenvironment in vitro. However, the effects of FLP on the tumor microenvironment in vivo are still poorly understood. The objective of this study is to investigate the effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase (Cox)-2 mediated tumor inflammatory microenvironment in vivo. 120 Lewis lung carcinoma xenograft mice were divided equally into four groups: vehicle, FLP, celecoxib, and FLP plus celecoxib. The dynamic growth of the xenografted tumors was observed using an in vivo fluorescence imaging system. Mice were sacrificed on day 14, day 21, and day 28, and tumor specimens and lung tissues were harvested to detect the metastasis-associated protein expression. Tumor inhibition rate was 15.4, 44.2, 47.4 % at day 14, 37.3, 34.7, 61.5 % at day 21, and 15.5, 10.3, 32.5 % at day 28 after treatment of FLP, celecoxib, and FLP plus celecoxib, respectively. Upon treatment of FLP and celecoxib together, lung metastasis rate was 30 % (8 metastatic nodules) lower than other groups. FLP inhibited Cox-2 expression in a time-dependent manner. Moreover, FLP inhibited N-cadherin, matrix metalloproteinases (MMP)-9, and Vimentin expression. Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors β, microsomal Prostaglandin E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression. FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 pathway. FLP in combination with celecoxib enhanced the antitumor growth and anti-metastasis effects. Traditional Chinese herbs combined with anti-inflammatory drugs might offer a promising strategy to prevent tumor metastasis.
- 23 November 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 366
Open AccessAnti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model
Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has been widely applied to treat lung cancer patients in China. Regulation of the metastatic microenvironment is an important therapeutic approach for prevention and treatment of tumor recurrence and metastasis. The advantage of Traditional Chinese Medicine management of lung cancer lies in the prevention of recurrence and metastasis. Our previous study has demonstrated that FLP ointment could regulate lung inflammatory microenvironment in vitro. However, the effects of FLP on the tumor microenvironment in vivo are still poorly understood. The objective of this study is to investigate the effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase (Cox)-2 mediated tumor inflammatory microenvironment in vivo. 120 Lewis lung carcinoma xenograft mice were divided equally into four groups: vehicle, FLP, celecoxib, and FLP plus celecoxib. The dynamic growth of the xenografted tumors was observed using an in vivo fluorescence imaging system. Mice were sacrificed on day 14, day 21, and day 28, and tumor specimens and lung tissues were harvested to detect the metastasis-associated protein expression. Tumor inhibition rate was 15.4, 44.2, 47.4 % at day 14, 37.3, 34.7, 61.5 % at day 21, and 15.5, 10.3, 32.5 % at day 28 after treatment of FLP, celecoxib, and FLP plus celecoxib, respectively. Upon treatment of FLP and celecoxib together, lung metastasis rate was 30 % (8 metastatic nodules) lower than other groups. FLP inhibited Cox-2 expression in a time-dependent manner. Moreover, FLP inhibited N-cadherin, matrix metalloproteinases (MMP)-9, and Vimentin expression. Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors β, microsomal Prostaglandin E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression. FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 pathway. FLP in combination with celecoxib enhanced the antitumor growth and anti-metastasis effects. Traditional Chinese herbs combined with anti-inflammatory drugs might offer a promising strategy to prevent tumor metastasis.